The role of topotecan in treating small cell lung cancer: second-line treatment [ J ]. Lung Cancer,2(X)3,41 ( Suppl 4 ) : S3 -S8.yon Pawel J, Asklepios F, Ganting BM, et al. The role of topotecan in treating small cell lung cancer: second-line treatment[J]. Lung Cancer,2003...
Lung CancerEttinger DS. New drugs for treating small cell lung cancer. Lung Cancer 1995 Jun; 12 Suppl. 3: S53–61Ettinger, D. S. (1995). New drugs for treating small cell lung can- cer. Lung Cancer 12(Suppl. 3), S53-S61.
Graham P, Boyages J. - Economic and quality-of-life aspects of treating small cell lung cancer. Pharma- coeconomics 1993; 3: 446-53.Graham P, Boyages J: Economic and quality-of-life aspects of treating small cell lung cancer. Pharmacoeconomics 1993, 3:446-453....
Hi. I was diagnosed with small cell lung cancer. I am treating my lung cancer with chemotherapy. They said surgery has no influence on survival. I am sick of ch This topic is answered by a medical expert.
Novel use of adapalene in treating cancerA novel use of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid or a pharmaceutically acceptable salt or functional derivative thereof in treating a cancer, and in particular non-small cell lung cancer, is provided.林志侯...
PRESENTATION COMPOSITIONS AND METHODS OF THESE TO TREAT SMALL CELL LUNG CANCERS AND NON-SMALL CELLS IN MAMMALS ARE PRESENTED. THE COMPOSITIONS INCLUDE SUBSTANCES WHICH INHIBIT THE PROLIFERATION AND GROWTH ACTIONS OF LUNG CANCER CELLS OF THE MODIFIED VASOACTIVE INTESTINAL VASOACTIVE LANDSCAPES, ASSOCIATED ...
1. A method of treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer comprising periodically administering to the human patient chemotherapy comprising an amount of docetaxel; and 640 mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAG...
In addition to the treatment of pancreatic cancer, GV1001 has also been developed for the treatment of other cancers, including melanoma, small cell lung cancer, prostate cancer, colorectal cancer, renal cell cancer, etc [102,103,104,105,106]. Its specific anticancer mechanisms include inhibition...
A549 nonsmall cell lung cancer cells express SCD1 protein and were growth inhibited in a dose dependent fashion by the SCD1 inhibitor, A939572 while Calu-1 lung cancer cells do not express SCD1 and are not growth inhibited by A939572 (see FIG. 14). Taxol is growth inhibitory in A549 bu...
Treating pa- tients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strate- gies to overcome it. Clin Transl Oncol 2017; 19: 658-666.Drizou M, Kotteas EA, Syrigos N. Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance ...